ViroPharma To Participate In The Stifel Nicolaus 2013 Healthcare Conference

 ViroPharma To Participate In The Stifel Nicolaus 2013 Healthcare Conference

PR Newswire

EXTON, Pa., Sept. 9, 2013

EXTON, Pa., Sept. 9, 2013 /PRNewswire/ -- ViroPharma Incorporated (Nasdaq:
VPHM) today announced that the company will present at the Stifel Nicolaus
2013 Healthcare Conference at 8:35 AM ET on Wednesday September 11, 2013. The
conference is being held at the Four Seasons Hotel in Boston.

ViroPharma's presentation will be webcast live for investors through
www.viropharma.comand available for a period of 14 days following the

About ViroPharma Incorporated

ViroPharma Incorporated is an international biopharmaceutical company
committed to developing and commercializing novel solutions for physician
specialists to address unmet medical needs of patients living with diseases
that have few if any clinical therapeutic options.ViroPharma is developing a
portfolio of therapeutics for rare and Orphan diseases including C1 esterase
inhibitor deficiency, cytomegalovirus (CMV), Friedreich's Ataxia, eosinophilic
esophagitis (EoE) and adrenal insufficiency. Our goal is to provide rewarding
careers to employees, to create new standards of care in the way serious
diseases are treated, and to build international partnerships with the
patients, advocates, and health care professionals we serve. ViroPharma's
commercial products address diseases including hereditary angioedema (HAE),
seizures in children and adolescents, adrenal insufficiency and C.
difficile-associated diarrhea (CDAD). For full U.S. prescribing information on
our products, please download the package inserts at; the prescribing information for other
countries can be found at

ViroPharma routinely posts information, including press releases, which may be
important to investors in the investor relations and media sections of our
company's web site, The company encourages investors to
consult these sections for more information on ViroPharma and our business.

SOURCE ViroPharma Incorporated

Contact: ViroPharma Incorporated, Robert A. Doody Jr., Director, Investor
Relations, (610) 321-6290
Press spacebar to pause and continue. Press esc to stop.